Quantitative Medicine
Drug development is complex, costly, and precarious. Too often, drug development decisions rely on incomplete integration of evidence or intuition—leading to avoidable risk, inefficiencies, and delay.
Quantitative medicine changes that. At its core, quantitative medicine is about making every data point count. It is an interdisciplinary approach that integrates biological, pharmacological, and pharmacokinetic concepts with compound, disease and competitor data into mathematical models. These models can turn scattered evidence into predictions allowing teams to anticipate outcomes, test “what-if” scenarios, and make decisions grounded in evidence rather than assumptions, thereby moving programs forward with greater confidence in probability of success and differentiation.
Simply said, a quantitative medicine strategy helps to make the most out of the data by creating insights and allow predictions for untested scenarios to guide drug development, regulatory and clinical use decisions.
How does Quantitative Medicine bring value?
Quantitative Medicine can unlock value by bringing novel therapeutics to patients with greater efficiency, lower development costs, and higher confidence in decision-making as evidenced by numerous reports (1,2,3,4,5,6).
Strengthen confidence. Quantitative Medicine builds confidence by replacing intuition with transparent, reproducible, and decision-ready analyses. Integrated modeling and simulation frameworks connect pharmacology, biomarkers, and clinical data into a coherent totality of evidence that supports benefit–risk assessment, labeling strategy, and regulatory dialogue. Scenario analyses and probability-of-technical-success framing sharpen development narratives for governance and investors alike, enabling clearer go/no-go decisions and more credible milestone delivery.
Accelerate timelines. By enabling right-first-time development strategies, Quantitative Medicine shortens development timelines and reduces re-work. Model-informed dose and regimen selection helps teams converge on pivotal doses with greater confidence. Model-based trial design, including informed power calculations, adaptive features, and population enrichment, improves translation and execution efficiency.
Reduce development costs. Quantitative Medicine reduces overall development spend by focusing resources on the most informative studies and avoiding unnecessary trials. Predictive analyses can enable early termination of low-probability programs, while PBPK approaches can predict drug–drug interactions and special population needs without defaulting to costly empirical studies. Re-use of data and insights from one program to another could accelerate indication expansion or development of drug with improved properties.
Quantitative Medicine across the life cycle
Quantitative Medicine can add value throughout the full drug development life cycle, from drug discovery, through development and regulatory approval, into life cycle management through a wide array of application areas such as quantifying differentiation potential, optimizing benefit–risk, informing trial design, selecting dose and regimen, and guiding translation from animal to man.
By using a wide range of pharmacometrics approaches ranging from empirical to deeply mechanistic, it supports decisions with varying levels of impact: low impact by strengthening and contextualizing experimental findings; medium impact by informing dose, regimen, and population selection; and high impact by replacing or streamlining experimental studies through predictive simulations.
These applications enable evidence-based decision making at the project level (go/no-go, dose selection, trial design), portfolio level (prioritization, probability of technical success, capital allocation), and regulatory level (labeling strategy, benefit–risk justification, model-informed submissions).
Success factors
Quantitative Medicine has a significant untapped potential to transform drug development. These approaches are still inconsistently applied across the biotech ecosystem, often due to limited awareness of their impact, fragmented execution, and gaps in accessible expertise. Realizing the full value of Quantitative Medicine requires a deliberate set of enablers that span data, technology, people, and governance, as well as timely initiation.
First, success depends on strong foundational data that characterize the compound, its mechanism of action, the disease biology, and the unmet need with current standard of care treatments. High-quality preclinical, translational, and clinical data provide the substrate on which quantitative models can reliably inform dose, regimen, and population decisions, as well as assessing the potential for differentiation.
Equally critical are skilled practitioners who operate as part of an integrated team effort, aligned with overall development strategy rather than functioning as a downstream service.
Also, sustained impact requires both a push from multidisciplinary project teams and a pull from decision makers (internal governance bodies, regulators, investors), who actively seek and rely on quantitative evidence to drive development, regulatory, and investment decisions.
Finally, modern enabling technologies, including AI/ML, digital twins, and advanced simulation platforms, expand the scale, speed, and scope of data use and quantitative insights. Looking ahead, these capabilities will no longer operate as standalone analytical exercises, but rather as intelligent AI agents that embed quantitative reasoning directly into development workflows, further maximizing its potential value.
We believe that there is a huge untapped therapeutic potential that can be unlocked by developing and embedding a quantitative medicine strategy timely into every stage of drug development—from discovery to approval and beyond—because it transforms uncertainty into clarity and can accelerate therapeutic innovation.
Ready to embed Quantitative Medicine into your next milestone? We can scope a focused plan around your most time-critical decisions.